5-HT1A receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats

International Journal of Neuropsychopharmacology

Volumn 12, Issue 8, 2009, Pages 1045-1053

  Sukoff Rizzo, Stacey J ^a   Pulicicchio, Claudine ^a   Malberg, Jessica E ^a   Andree, Terrance H ^a   Stack, Gary P ^a   Hughes, Zo A ^a   Schechter, Lee E ^a   Rosenzweig Lipson, Sharon ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT1A; Antidepressants; Fluoxetine; Sexual dysfunction; SSA 426

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SSA 426; UNCLASSIFIED DRUG; WAY 101405;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG INDUCED DISEASE; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; FEMALE; FEMALE SEXUAL DYSFUNCTION; MALE; MALE SEXUAL DYSFUNCTION; NONHUMAN; OLFACTORY BULBECTOMY; PENIS ERECTION; PRIORITY JOURNAL; RAT; SEXUAL FUNCTION;

AMINOPYRIDINES; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; FEMALE; FLUOXETINE; MALE; OLFACTORY BULB; OVARIECTOMY; PIPERAZINES; RATS; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TIME FACTORS;

EID: 69749083928     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709000406     Document Type: Article

References (27)

1. Adell A, Castro E, Celada P, Bortolozzi A, et al. (2005). Strategies for producing faster acting antidepressants. Drug Discovery Today 10, 578-585.
2. Ahlenius S, Larsson K (1998). Evidence for an involvement of 5-HT1B receptors in the inhibition of male rat ejaculatory behavior produced by 5-HTP. Psychopharmacology 137, 374-382.
3. Ahlenius S, Larsson K (1999). Synergistic actions of the 5-HT1A receptor antagonist WAY-100635 and citalopram on male rat ejaculatory behavior. European Journal of Pharmacology 379, 1-6.
4. Artigas F (1993). 5-HT and antidepressants: new views from microdialysis studies. Trends in Pharmacological Sciences 14, 262.
5. Artigas F, Romero L, de Montigny C, Blier P (1996). Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends in Neuroscience 19, 378-383. (Pubitemid 26270513)
6. Baldwin D, Hutchison J, Donaldson K, Shaw B, et al. (2008). Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. Journal of Psychopharmacology 22, 55-63.
7. Chemel BR, Roth BL, Armbruster B, Watts VJ, et al. (2006). WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology 188, 244-251.
8. Coleman CC, King BR, Bolden-Watson C, Book MJ, et al. (2001). A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clinical Therapeutics 23, 1040-1058.
9. Croft H, Settle Jr. E, Houser T, Batey SR, et al. (1999). A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clinical Therapeutics 21, 643-658.
10. Cryan JF, McGrath C, Leonard BE, Norman TR (1999). Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat. Pharmacology Biochemistry and Behavior 63, 333-338.
11. Dawson LA, Nguyen HQ (1998). Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in serotonin in rat frontal cortex. European Journal of Pharmacology 345, 41-46.
12. de Jong TR, Pattij T, Veening JG, Dederen PJ, et al. (2005). Citalopram combined with WAY-100635 inhibits ejaculation and ejaculation-related Fos immunoreactivity. European Journal of Pharmacology 509, 49-59.
13. Ferguson JM (2001). The effects of antidepressants on sexual functioning in depressed patients: a review. Journal of Clinical Psychiatry 62, 22-34.
14. Forster EA, Cliffe IA, Bill DJ, Dover GM, et al. (1995). A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. European Journal of Pharmacology 281, 81-88.
15. Hirst WD, Andree TH, Aschmies S, Childers WE, et al. (2008). Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-pipiperazinyl) ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405). Journal of Pharmacology and Experimental Therapeutics 325, 134-145.
16. Hjorth S, Westlin D, Bengtsson HJ (1997). WAY-100635-induced augmentation of the 5-HT elevating action of citalopram - relative importance of the dose of the 5-HT1A (auto)receptor blocker vs. that of the 5-HT reuptake inhibitor. Neuropharmacology 36, 461-465.
17. Hornby GA, Stack G, Dawson LA, Nguyen HQ, et al. (2004). SSRI/5-HT1A antagonists as future antidepressant agents: A neurochemical assessment of SSA-426. Abstracts of the 34th Annual Society for Neuroscience Conference, 1024.14.
18. Hsieh GC, Hollingsworth PR, Martino B, Chang R, et al. (2004). Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. Journal of Pharmacology and Experimental Therapeutics 308, 330-338.
19. Landen M, Erikkson E, Agren H, Fahlen T (1999). Effects of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology 19, 268-271.
20. Looney C, Thor KB, Ricca D, Marson L (2005). Differential effects of simultaneous or sequential administration of paroxetine and WAY-100635 on ejaculatory behavior. Pharmacology Biochemistry and Behavior 82, 427-433.
21. Lorrain DS, Matuszewich L, Friedman R, Hull EM (1997). Extracellular serotonin in the lateral hypothalamic area increases during the postejaculatory interval and impairs copulation in male rats. Journal of Neuroscience 17, 9361-9366.
22. Marson L, McKenna KE (1992). A role for 5-hydroxytryptamine in descending inhibition of spinal sexual reflexes. Experimental Brain Research 88, 313-320.
23. Martel JC, Leduc N, Ormière AM, Faucillon V, et al. (2007). WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. European Journal of Pharmacology 574, 15-19.
24. National Research Council (1996). Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press.
25. Norden MJ (1994). Buspirone treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Depression 2, 109-112.
26. Sharp T, Umbers V, Gartside SE (1997). Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. British Journal of Pharmacology 121, 941-946.
27. Sukoff Rizzo SJ, Schechter LE, Rosenzweig-Lipson S (2008). A novel approach for predicting antidepressant-induced sexual dysfunction in rats. Psychopharmacology 195, 459-467.